Recent investigations have converged on the overlap of GLP|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine communication. While GIP agonists are widely employed for managing type 2 diabetes mellitus, their unexpected impacts on motivation circuits, specifically mediated by dopamine pathways, are receiving signific